ESMO 2018: The Best of Munich 2018 Congress - Genitourinary Tumors, Non-Prostate
Munich, Germany (UroToday.com) Dr. Bono discussed some of the highlights in renal and bladder cancer that were presented this year in ESMO 2018, in Munich. He first discussed some of the interesting studies in renal cancer. In the last ten years, there have been ten new agents that have been made available for the treatment of metastatic renal cell carcinoma (mRCC). The median survival of these new agents is approximately 28-30 months.
ESMO 2018: Challenging Established Frontline Therapies in Renal Cancer
Munich, Germany (UroToday.com) Dr. Laurence Albiges gave a talk on the challenges faced by established frontline therapies in renal cancer. In the ESMO meeting in 2017, the Checkmate 214 trial was presented, which compared sunitinib to Nivolumab + ipilimumab in the treatment of metastatic renal cell carcinoma (mRCC) patients. This trial demonstrated a benefit in favor of the nivolumab + ipilimumab combination in poor and intermediate risk mRCC patients, with median overall survival (OS) that was not reached compared to 26 months in the sunitinib group, p<0.0001. The complete response rate (CR) was 9% vs. 1% in favor of the combination treatment.
ESMO 2018: WHO-ESMO Workforce Survey: How Can your Country Assure Enough Oncologists for the Future?
Munich, Germany (UroToday.com) When analyzing what kind of health workforce is required in any specific environment. It is important to answer some raised relevant questions:
- How many providers are needed?
- What type of providers are needed?
- How to organize and distribute providers?
- How to ensure providers are adequately trained to provide high-quality care.
ESMO 2018: Where Does the World Stand on Global Cancer Control?
Munich, Germany (UroToday.com) Cancer causes 9.6 million deaths per year worldwide (1 in 6 global deaths). This is a higher number than that caused by AIDS, Malaria, and Tuberculosis, combined! Unfortunately, being diagnosed with cancer in a low-income country results in chances of survival of less than 30%. The cancer burden is expected to rise significantly from 18.1 million cases per year in 2018 to 29.9 million cases per year in 2040.
ESMO 2018: Invited Discussant - Interrogating Genomics of Prostate Cancer for Precision Medicine Based on DNA Repair Defects
Munich, Germany (UroToday.com) Joaquin Mateo, MD gave a summary presentation on three major posters presented ESMO 2018. These posters included: 1. 793PD - Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations – Wassim Abida, New York, US. 2. 794PD - Prospective comprehensive genomic profiling (CGP) of 3,476 primary and metastatic site prostate tumors – Siraj Ali, Cambridge, US. 3. 795PD - Genomic profiling of circulating tumor DNA (ctDNA) and tumor tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC) – Simon Chowdhury, London, UK
ESMO 2018: Invited Discussant - Detection of Circulating Tumor DNA in mHSPC and LATITUDE Study
Munich, Germany (UroToday.com) Joe O’Sullivan, MD, gave a discussion summarizing two important posters presented at ESMO 2018 in Munich. These included:
- 796PD - Detection of circulating tumor DNA in de novo metastatic castrate-sensitive prostate cancer – Werner Strauss et al.
- 797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival in patients with metastatic hormone-sensitive prostate cancer receiving ADT+abiraterone acetate and prednisone or placebo – Nobiaki Matsubara et al.
ESMO 2018: Invited Discussant - mCRPC with High Tumor Mutational Burden and a Phase I Dose-Escalation Study of 177Lu-PSMA-617 for mCRPC
Munich, Germany (UroToday.com) Aristotelis Bamias, MD discussed the following two studies:
- 798PD - In-depth assessment of metastatic prostate cancer with the high tumor mutational burden – Niven Mehra et al.
- 799PD - Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC) – Scott Tagawa et al.